BioPharma Dive November 20, 2024
U.S. biotechs and pharmas will likely still have to cut ties with certain Chinese partners — it’s just a matter of when.
With the Trump administration preparing to take office, the Biosecure Act is in something of a legislative limbo. The bill, which would require U.S. companies to sever contracts with some Chinese manufacturing and research organizations, is now in the hands of a lame duck Congress.
Even if Congress doesn’t pass the bill as one of its last acts, it has bipartisan support and rhetoric from President-elect Donald Trump around U.S.-Chinese relations could add momentum for its passage once he’s sworn into office.
“A Trump win brings uncertainty along a number of fronts for the biopharma industry, but one...
Today's Sponsors
Today's Sponsor